MedinCell publishes its financial results and activity report for the first half of 2021-2022 December 8, 2020 December 8, 2020
Videoconference and publication of the 2020-2021 Half-Year Results, on December 9, 2020 December 2, 2020 December 2, 2020
First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date November 12, 2020 November 12, 2020
Convening of the General Assembly: Proposal for the appointment of Elisabeth Kogan to the Supervisory Board November 9, 2020 November 9, 2020
MedinCell initiates the first clinical trial of its Covid-19 prevention program September 29, 2020 September 29, 2020
MedinCell releases the results of its September 10, 2020 ordinary annual and extraordinary general meeting September 11, 2020 September 11, 2020
Participation terms in the MedinCell Combined General Meeting and availability of preparatory documents July 31, 2020 July 31, 2020
MedinCell announces the availability of its 2019/2020 Universal Registration Document including the Annual Financial Report July 29, 2020 July 29, 2020
MedinCell announces the great success of its capital increase and raises 15.6 M€ June 16, 2020 June 16, 2020
MedinCell successfully renegotiates the drawdown conditions of the last tranche of the EIB loan and secures an additional €5m of non-dilutive funding June 10, 2020 June 10, 2020
MedinCell announces fiscal year consolidated results April 2019 – March 2020 June 4, 2020 June 4, 2020
